Physician profile
Shane Larue
NPI 1811955180
$40,758.54
in general payments reported to CMS, 2019-2025
10 companies · $6,319 in 2025
The $6,319 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.85 · 2022: $9,102 · 2023: $8,972 · 2024: $16K · 2025: $6,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Consulting Fee: $8,700 · Food and Beverage: $873 · Travel and Lodging: $758 · Education: $37.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,250.00 |
| Consulting Fee | $8,700.00 |
| Food and Beverage | $872.93 |
| Travel and Lodging | $758.28 |
| Education | $37.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $29,654.96 | 2022-2024 | Camzyos |
| Pfizer INC. | $6,274.99 | 2023-2025 | |
| Cvrx, INC. | $4,708.67 | 2024-2025 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.70 | 2025 | Jardiance |
| Daiichi Sankyo INC. | $24.21 | 2024 | Injectafer |
| Abbott Laboratories | $23.54 | 2021 | |
| Heartflow, INC. | $20.16 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.31 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Larue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.